Work

Figure S2 from Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas

Year: 2023

Type: other

Abstract: Cell viability assays were performed using the Celltiter-Glo Luminescent Cell Viability Assay in representative MCL primary cells (PT-2 and PT-6) treated with increasing concentrations of ibrutinib (A) or idelalisib (B).

DOI: 10.1158/1078-0432.22467461.v1

Authors: Lan V. Pham, Shengjian Huang, Hui Zhang, Jun Zhang, Taylor Bell, Shouhao Zhou, Elizabeth Pogue, Zhiyong Ding, Laura Lam, Jason Westin, R. Eric Davis, Ken H. Young, L. Jeffrey Medeiros, Richard J. Ford, Krystle Nomie, Leo Zhang, Michael Wang

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361967896

Cites:

Cited by:

Related to: 10